Autolus Therapeutics (AUTL)

• Market cap: $394M
• 1 day: 1.37%
• 5 days: -9.76%
• 1 month: -6.33%
• 3 months: -7.5%
• 6 months: -3.27%
• Year to date: -20.86%
• 1 year: -36.48%
• 5 years: -78.39%
• 10 years: -94.08%
• Sector: Healthcare
• Industry: Biotechnology

About: Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Employees: 752